Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Nuvalent, Inc. (NUVL) reported an insider transaction by its Chief Development Officer on 10/30/2025. The officer exercised 4,000 stock options at $27.85 and, the same day, sold 4,000 Class A shares across multiple trades, executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
The reported sales were in tranches including 57 shares at $98.91 (weighted average, range $98.16–$99.13) and additional lots at weighted average prices of $100.69, $102.07, $103.09, $104.21, and a final sale at $104.58. Following these transactions, the officer directly held 48,034 Class A shares. Derivative holdings reported after the exercise were 122,329 stock options outstanding, with the option series expiring on 01/06/2033 and vesting monthly over four years from January 6, 2023.
Nuvalent (NUVL) reported insider activity by its Chief Legal Officer on 10/30/2025. The officer exercised 21,800 stock options at an exercise price of $6.89 and sold an equal 21,800 Class A shares in multiple same‑day open‑market transactions with weighted average prices disclosed for each tranche.
Tranche prices reported include weighted averages of $96.65, $97.98, $99.66, $100.96, $102.00, $102.88, $103.90, and $104.78. Following the transactions, the officer directly owned 49,086 shares. The filing notes the trades were effected under a Rule 10b5-1 plan adopted on November 18, 2024, and the option exercised was fully vested; 118,808 derivative securities were beneficially owned after the transactions.
Nuvalent, Inc. (NUVL) reported a larger quarterly loss while advancing its oncology pipeline. For Q3 2025, net loss was $122.4 million versus $84.3 million a year ago as operating expenses rose with clinical activity. Research and development reached $83.8 million (from $60.6 million) and general and administrative was $28.9 million (from $15.8 million).
Liquidity remains strong with cash, cash equivalents and marketable securities of $943.1 million as of September 30, 2025. The company reported an accumulated deficit of $853.7 million and noted its resources are expected to fund operations into 2028. The fair value of a related party revenue share liability increased to $45.2 million from $17.9 million, reflecting updated assumptions.
Program updates included completion of a rolling NDA for zidesamtinib in TKI pre-treated ROS1-positive NSCLC and ongoing Phase 2 work in TKI-naïve patients. Neladalkib advanced with Phase 2 enrollment completed in TKI pre-treated NSCLC and initiation of the Phase 3 ALKAZAR trial in TKI‑naïve ALK‑positive NSCLC. NVL‑330 progressed in Phase 1 with new preclinical data highlighting brain‑penetrant properties.
Nuvalent, Inc. filed a current report to share that it announced its financial results for the quarter ended September 30, 2025, along with other corporate updates. The company furnished a press release as Exhibit 99.1, which contains the detailed quarterly results and information. This material is being treated as “furnished” rather than “filed,” meaning it is not subject to certain liability provisions under the securities laws or automatically incorporated into other SEC filings unless specifically referenced.
Nuvalent (NUVL) director Matthew D. Shair reported open-market sales of Class A common stock executed under a Rule 10b5-1 trading plan adopted on November 20, 2024.
On 10/27/2025, he sold 14,345 shares at a weighted average price of $100.23 and 4,046 shares held indirectly by the Matthew D. Shair 2021 Irrevocable Family Trust at a weighted average price of $100.23. On 10/28/2025, he sold 32,455 shares at a weighted average price of $100.27 and 9,154 indirect shares at a weighted average price of $100.27. Following these transactions, he beneficially owned 1,383,044 shares directly and 203,322 shares indirectly.
Nuvalent, Inc. (NUVL) reported an insider transaction by its Chief Legal Officer. On 10/20/2025, the officer exercised 5,000 stock options at an exercise price of $6.89 per share and sold 5,000 Class A shares at a weighted average price of $94.91 (range $94.80–$95.00). These trades were executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
Following the transactions, the reporting person directly beneficially owned 49,086 Class A shares and held 140,608 derivative securities (stock options) with an option expiration date of 04/29/2031. The filing notes the underlying option shares are fully vested.
Nuvalent (NUVL): CEO insider transaction — On 10/16/2025, the President and CEO (also a Director) exercised 27,000 stock options at $18.93 per share and sold an aggregate 27,000 Class A shares in multiple tranches pursuant to a Rule 10b5-1 trading plan.
Weighted-average sale prices by tranche were $90.01 for 11,310 shares, $90.91 for 13,876 shares, $92.19 for 1,114 shares, and $92.63 for 700 shares. Following these transactions, the reporting person beneficially owned 249,062 Class A shares directly. Derivative holdings reported include 222,400 stock options remaining after the exercise.
Nuvalent, Inc. (NUVL): The Chief Legal Officer reported option exercises and open-market sales under a Rule 10b5-1 plan. On 10/15/2025, 15,624 Class A shares were acquired via option exercise at $6.89 and 15,624 shares were sold at a weighted average price of $89.98. On 10/16/2025, 12,376 shares were acquired via option exercise at $6.89, followed by sales of 2,277 shares at a weighted average price of $90.54, 5,199 shares at $91.37, and 4,900 shares at $92.5.
Following these transactions, the reporting person directly owned 49,086 Class A shares. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024. After the exercises, stock options (right to buy) remaining were 145,608 at a $6.89 exercise price, fully vested, expiring on 04/29/2031.
Nuvalent (NUVL) reported insider activity by its Chief Scientific Officer. On 10/15/2025, the officer exercised stock options for 3,668 shares at $18.93, 7,495 shares at $27.85, and 3,042 shares at $72.35, then sold 14,205 Class A shares at a weighted average price of $90.04 (range $89.84–$90.23).
The transactions were made under a Rule 10b5-1 trading plan adopted on November 1, 2024. Following these trades, the officer directly beneficially owned 65,963 Class A shares.
Nuvalent (NUVL) reported an insider transaction by its Chief Financial Officer. On 10/15/2025, the CFO exercised 1,683 stock options at $18.93 per share and sold 1,683 Class A shares at a weighted average price of $85.57, with individual sales ranging from $85.00 to $85.69. The trades were made under a Rule 10b5-1 plan adopted on December 12, 2024.
Following these transactions, the CFO beneficially owned 61,734 Class A shares directly and 28,979 derivative securities (stock options). The filing lists transaction codes M (option exercise) and S (sale).